Director’s Report to the
National Advisory Council
on Drug Abuse
May 16, 2007
Director’s Report to the
National Advisory Council on Drug Abuse
Budget Update
Recent NIDA Activities
What’s New @ NIH?
NIDA BUDGET
(Thousands)
IncreaseIncrease
OverOver
Prior YearPrior Year
AIDSAIDS
TOTALTOTAL
NonAIDSNonAIDS $693,282
$313,13...
$0
$2
$4
$6
$8
$10
$12
$14
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Fiscal Year
Solicited Unsolicited
R...
0%
5%
10%
15%
20%
25%
30%
35%
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Fiscal Year
SuccessRate
Solicite...
Responses to Requests for Applications
NIH New (Type 1) Research Project Grant Awards
0%
10%
20%
30%
40%
50%
60%
70%
80%
9...
NIDA Dashboard
New PIs
Medicinal
Chemists
-- Recruitment
-- Training
Collaborations? ?
?
FY 2008 Budget Hearings
• March 1, 2007 -- House Appropriations Subcommittee on Labor, HHS
and Education Hearing on FY 200...
IC Directors’ Retreat – May 17-18, 2007
Roadmap II
Top 5 Topics Strategic Planning Groups
1) Microbiome
2) Protein Capture...
Epigenetic Mechanisms Regulate How Genetic
Information Is Expressed Across Development,
Tissue, Environment and Disease St...
Epigenetic Marks Are Altered in Common
Brain Disorders Including Addiction
Timeline for Epigenetics Program
RM/IC Projects
Technology
Development
RFA#3
Data Management
Center
Mapping Centers
JUMPST...
National Institute on Drug Abuse
Special Populations Office
Division of
Basic Neurosciences
& Behavior Research
Office of
...
0
5
10
15
20
25
30
35
40
45
50
AIDS
Extramural
Non-AIDS
Extramural
Oct-04 Jan-05 May-05 Oct-05 Jan-06 May-06
Success Rates...
Strategies of NIDA’s Investment on AIDS
. NIDA Staff Meetings
to identify priority areas
• March 12, 2007
• April 9, 2007
...
Changing Nature of the HIV Epidemic
• Infrastructure:
facilitate access to existing cohorts (ALIVE, MLS)
proteomic analysis
animal models
• Innovative researc...
National Institute on Drug Abuse
Special Populations Office
Division of
Basic Neurosciences
& Behavior Research
Office of
...
Convergence of HIV Seroprevalence Among
Injecting and Non-injecting Drug Users
0
5
10
15
20
Current Injectors Non-Injector...
National Institute on Drug Abuse
Special Populations Office
Division of
Basic Neurosciences
& Behavior Research
Office of
...
Young caucasians are at elevated HIV risk when they engage in risky behaviors;
whereas young AA are at high risk even when...
National Institute on Drug Abuse
Special Populations Office
Division of
Basic Neurosciences
& Behavior Research
Office of
...
Effects of Statins on the Interactions of HIV-1-Infected
T Cells with Neurons With and Without ETOH on the
Oxidative Stres...
National Institute on Drug Abuse
Special Populations Office
Division of
Basic Neurosciences
& Behavior Research
Office of
...
• 1,000,000 people in USA are
infected with HIV
– 40,000 new cases each year
– 25 % of persons with HIV
are unaware they a...
National Institute on Drug Abuse
Special Populations Office
Division of
Basic Neurosciences
& Behavior Research
Office of
...
Injectable Sustained-Release Naltrexone
for Opioid Dependence Treatment
Injectable Sustained-Release Naltrexone
for Opioid...
Brain Imaging Drug Use Prevention
Messages (R21)
(RFA-DA-07-007) – 16 Applications
DCNBR and DESPR
Mechanisms of Drug Abuse Interactions
with HIV Neuropathogenesis
(R01--RFA-DA-07-002) – 14 Applications
(R21--RFA-DA-07-00...
Design, Synthesis, and Preclinical Testing
of Potential Treatment Agents for
Drug Addiction (R01)
(RFA-DA-07-006) – 30 App...
Recent and Upcoming Meetings,
Conferences and Events
The Addiction Project’s Audience is estimated to be
over 50 million impressions…and counting
• Including…
• HBO Channels –...
Timothy P. Condon, Ph.D.
Deputy Director, NIDA
Gregory Brigham, Ph.D.
CRO, Maryhaven
Dennis McCarty, Ph.D.
Oregon Health S...
ACNP American College of
Neuropsychopharmacology
Liaison Committee
Opportunities and Impediments to
Drug Development for
A...
Director's Report to the National Advisory Council on - PowerPoint ...
Upcoming SlideShare
Loading in...5
×

Director's Report to the National Advisory Council on - PowerPoint ...

276

Published on

Published in: Technology, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
276
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • <number>
    Data Check: Complete
  • <number>
    This is the new chart showing success rates for all RPG’s.
    Data Check: Complete
  • <number>
  • Director's Report to the National Advisory Council on - PowerPoint ...

    1. 1. Director’s Report to the National Advisory Council on Drug Abuse May 16, 2007
    2. 2. Director’s Report to the National Advisory Council on Drug Abuse Budget Update Recent NIDA Activities What’s New @ NIH?
    3. 3. NIDA BUDGET (Thousands) IncreaseIncrease OverOver Prior YearPrior Year AIDSAIDS TOTALTOTAL NonAIDSNonAIDS $693,282 $313,137 2005 Actual $1,006,419 +1.2% $698,976 $299,882 2006 Actual $998,858 -0.8% 2007 C.R. $699,349 $300,073 $999,422 +0.1% 2008 P.B. $699,908 $300,457 $1,000,365 +0.1%
    4. 4. $0 $2 $4 $6 $8 $10 $12 $14 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 Fiscal Year Solicited Unsolicited RPG* Funding, Unsolicited and Solicited * Research Projects are part of research grants, limited to activity codes R01, R03, R15, R21, R22, R23, R29, R33, R34, R35, R36, R37, R55, R56, P01, P42, PN1, UC1, U01, U19 and DP1. No NLM awards are considered to be research projects. Solicited awards are responses to Requests for Applications (RFA’s). Funding(inbillions)
    5. 5. 0% 5% 10% 15% 20% 25% 30% 35% 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 Fiscal Year SuccessRate Solicited Unsolicited * Research Projects are part of research grants, limited to activity codes R01, R03, R15, R21, R22, R23, R29, R33, R34, R35, R36, R37, R55, R56, P01, P42, PN1, UC1, U01, U19 and DP1. No NLM awards are considered to be research projects. Solicited awards are responses to Requests for Applications (RFA’s). Success Rates of Solicited and Unsolicited Competing RPG* Applications
    6. 6. Responses to Requests for Applications NIH New (Type 1) Research Project Grant Awards 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% AI D E R R H G ES AAN IH Total D A D K H L AG M H H D C A EY D C AR N R N S G M TW Institute/Center PercentofTotal FY 1998 FY 2006 I/C’s are arrayed by percent of funding for new RPG’s spent for responses to program announcements in FY 2006
    7. 7. NIDA Dashboard New PIs Medicinal Chemists -- Recruitment -- Training Collaborations? ? ?
    8. 8. FY 2008 Budget Hearings • March 1, 2007 -- House Appropriations Subcommittee on Labor, HHS and Education Hearing on FY 2008 President’s Budget Request for SAMHSA, NIDA, NIAAA and NIMH • March 6, 2007 -- House Appropriations Subcommittee on Labor, HHS and Education Hearing on FY 2008 President’s Budget Request for NIH • March 19, 2007 – Senate Appropriations Subcommittee on Labor, HHS and Education Hearing on FY 2008 President’s Budget Request for NIH • March 26, 2007 – Senate Appropriations Subcommittee on Labor, HHS, and Education FY 2008 Budget for Mind, Brain and Behavioral Research
    9. 9. IC Directors’ Retreat – May 17-18, 2007 Roadmap II Top 5 Topics Strategic Planning Groups 1) Microbiome 2) Protein Capture/Proteome Tools 3) Phenotyping Services, Tools 4) Inflammation 5) Epigenetics a) Training/Careers b) Health Disparities c) Science of Science d) Pharmacogenomics
    10. 10. Epigenetic Mechanisms Regulate How Genetic Information Is Expressed Across Development, Tissue, Environment and Disease States 0 500 1000 1500 2000 2500 3000 3500 4000 4500 1990 1992 1994 1996 1998 2000 2002 2004 2006 Epigenetics Epigenetics + Disease Citations for Epigenetics DNA Methylation – silences gene Histone Modification – methylation, acetylation, or phosphorylation Non coding RNA
    11. 11. Epigenetic Marks Are Altered in Common Brain Disorders Including Addiction
    12. 12. Timeline for Epigenetics Program RM/IC Projects Technology Development RFA#3 Data Management Center Mapping Centers JUMPSTART FY08 FY09 FY10 FY11 FY12 RFA#1 RFA#4 RFA#2 FY13 FY14 FY15 FY16 FY17 • 24 comprehensive reference epigenomes • Cell/tissue variation assessed • New Ab reagents for epigenomics • Public resource (cells/tissue, data, tools) • International Consortium • Standardization • Reagents (Abs) • Establish/maintain public data resource (via NCBI) • New tools for data integration, analysis, and viewing Develop/adapt new tools, application to RM and IC projects RFA1 RFA2 RFA3 RFA4 RFA5 Co-fund up to 15 IC-based programs RFA1 RFA2 RFA3 RFA4 FY07 TRANSITIONtoICs
    13. 13. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Teresa Levitin, PhD Donna M. Jones (Acting) Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS ResearchDirector, AIDS Research
    14. 14. 0 5 10 15 20 25 30 35 40 45 50 AIDS Extramural Non-AIDS Extramural Oct-04 Jan-05 May-05 Oct-05 Jan-06 May-06 Success Rates for AIDS Extramural and Non-AIDS Extramural Percent
    15. 15. Strategies of NIDA’s Investment on AIDS . NIDA Staff Meetings to identify priority areas • March 12, 2007 • April 9, 2007 . Scientific Meeting of Experts May 8-9, 2007 Uncommitted Funds FY06 FY07 FY08 FY09 FY10 $40M $58M $65M ~$60M ~$60M In collaboration with: National Institute on Alcohol Abuse and Alcoholism National Institute of Allergy and Infectious Diseases National Institute of Child Health and Human Development National Institute of Mental Health Centers for Disease Control and Prevention
    16. 16. Changing Nature of the HIV Epidemic
    17. 17. • Infrastructure: facilitate access to existing cohorts (ALIVE, MLS) proteomic analysis animal models • Innovative research: Avant-Garde Award (equivalent to Pioneer Award) • International: Create clinical and basic research networks Training: e.g., Invest Fellows/China/CTN Integrate research with NIAID international networks HIV/AIDS Mechanisms
    18. 18. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Science Policy & Communications Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research DESPR Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting)
    19. 19. Convergence of HIV Seroprevalence Among Injecting and Non-injecting Drug Users 0 5 10 15 20 Current Injectors Non-Injectors HIVPrevalence 13% CI 12-15% 12% CI 9-16% Drug Treatment Program (n=2121 2001-2004) Respondent-Driven Sampling (n=448 2004) 0 5 10 15 20 Current Injectors Non-Injectors 15% CI 11-19% 17% CI 12-21% Source: Des Jarlais et al AIDS, 21: 231-235, 2007.
    20. 20. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Science Policy & Communications Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research DCNBR Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting)
    21. 21. Young caucasians are at elevated HIV risk when they engage in risky behaviors; whereas young AA are at high risk even when their behaviors are normative. Source: Hallfors et al Am J Public Health. 2007 97:125-32, 2007. Caucasian (n=6257) 0 5 10 15 20 25 30 35 Few partners, low ATOD Binge drinking THC use Multiple partners Sex money IDU MSM Drug use AA (n=2449) PrevalenceHIV/STD National Longitudinal Longitudinal Study of Adolescent Health. 18 to 26 years old Sexual & Drug Behavior Patterns & HIV & STD: Racial Disparities
    22. 22. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Science Policy & Communications Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research DBNBR Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting)
    23. 23. Effects of Statins on the Interactions of HIV-1-Infected T Cells with Neurons With and Without ETOH on the Oxidative Stress Marker, Heat Shock Protein 70 (Hsp70) 0.3% EtOH Statins Protect Human Neurons against EtOH- & HIV Type 1-Induced Oxidative Stress In Vitro Source: Acheampong et al. J Virol. 81:1492-1501, 2007. Ator, atorvastatin; Simva, simvastatin
    24. 24. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Science Policy & Communications Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research Update from Dr. Betty Tai this morning Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting) CCTN
    25. 25. • 1,000,000 people in USA are infected with HIV – 40,000 new cases each year – 25 % of persons with HIV are unaware they are infected – ¼ of persons who test HIV+ fail to return to receive results • CDC now recommends offering routine HIV testing to persons at risk for HIV • 1,000,000 people in USA are infected with HIV – 40,000 new cases each year – 25 % of persons with HIV are unaware they are infected – ¼ of persons who test HIV+ fail to return to receive results • CDC now recommends offering routine HIV testing to persons at risk for HIV Integrating HIV Rapid Testing and CounselingIntegrating HIV Rapid Testing and Counseling into Drug Treatmentinto Drug Treatment • FDA approved • blood from a finger stick or oral fluid • 20 minutes • $12-15/kit • can be done by counselors HIV Rapid Test
    26. 26. National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Science Policy & Communications Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research DPMCDA Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting)
    27. 27. Injectable Sustained-Release Naltrexone for Opioid Dependence Treatment Injectable Sustained-Release Naltrexone for Opioid Dependence Treatment Sustained release naltrexone produced a robust, dose-related increase in treatment retention and in drug-free urines in heroin dependent subjects (n=60) Source: Comer et al., Arch Gen Psychiatry. 63:210-218, 2006.
    28. 28. Brain Imaging Drug Use Prevention Messages (R21) (RFA-DA-07-007) – 16 Applications DCNBR and DESPR
    29. 29. Mechanisms of Drug Abuse Interactions with HIV Neuropathogenesis (R01--RFA-DA-07-002) – 14 Applications (R21--RFA-DA-07-003) – 13 Applications Extinction and Pharmacotherapies for Drug Addiction (R01--RFA-DA-07-010) -- 15 Applications (R03--RFA-DA-07-011) -- 12 Applications
    30. 30. Design, Synthesis, and Preclinical Testing of Potential Treatment Agents for Drug Addiction (R01) (RFA-DA-07-006) – 30 Applications Development of Immunotherapeutic Products for the Treatment of Methamphetamine Addiction (U01) (RFA-DA-07-004) – 5 Applications
    31. 31. Recent and Upcoming Meetings, Conferences and Events
    32. 32. The Addiction Project’s Audience is estimated to be over 50 million impressions…and counting • Including… • HBO Channels – over 13 million viewers • HBO on Demand – nearly 1 million orders • DVD – more than 30,000 sold • Companion Book – over 7,000 sold • Podcasts – over 380,000 downloads • Online – hbo.com/addiction, AOL & cable affiliate websites – over 600,000 video streams & 2.9 million page views
    33. 33. Timothy P. Condon, Ph.D. Deputy Director, NIDA Gregory Brigham, Ph.D. CRO, Maryhaven Dennis McCarty, Ph.D. Oregon Health Sciences University
    34. 34. ACNP American College of Neuropsychopharmacology Liaison Committee Opportunities and Impediments to Drug Development for Alcoholism and Other Substance Abuse The National Press Club Washington, D.C. May 20, 2007
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×